Search Results

You are looking at 261 - 270 of 1,257 items for :

  • Refine by Access: All x
Clear All
Full access

Jenna F. Borkenhagen, Daniel Eastwood, Deepak Kilari, William A. See, Jonathan D. Van Wickle, Colleen A. Lawton, and William A. Hall

,294,126 incident cases in the prostate PUF for 2004 through 2010. Of these, the subset of men with high-risk clinical T2N0M0 prostate cancer treated with curative-intent external-beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) ± surgery was

Full access

Yoshikuni Kawaguchi, Scott Kopetz, Heather A. Lillemoe, Hyunsoo Hwang, Xuemei Wang, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia, and Jean-Nicolas Vauthey

CLM resection is to detect recurrence early, when both the patient and the disease recurrence are treatable. Repeat surgery is effective for recurrence after CLM resection. Reported 5-year overall survival (OS) rates in patients who undergo resection

Full access

Joe Y. Chang and Vivek Verma

less commonly surgery or thermal ablative therapy) for oligometastatic and oligoprogressive disease is to provide potentially curative-intent therapy to the limited existing sites of gross disease, assuming that systemic therapy can address

Full access

Siyang Leng, Yizhen Chen, Wei-Yann Tsai, Divaya Bhutani, Grace C. Hillyer, Emerson Lim, Melissa K. Accordino, Jason D. Wright, Dawn L. Hershman, Suzanne Lentzsch, and Alfred I. Neugut

-related event (SRE). 4 , 5 Considerable evidence from randomized controlled trials supports the use of bisphosphonates. Pamidronate and zoledronic acid have been shown to significantly reduce SREs (defined as pathologic fracture, radiation to bone, surgery on

Full access

Timothy J. Wilt and Philipp Dahm

the United Kingdom–based ProtecT screening trial are expected soon and will be informative. 16 Recent treatment trials for localized disease demonstrate that reductions as a result of surgery compared with observation in prostate cancer or all

Full access

Timothy Paul Hanna, Geoffrey Paul Delaney, and Michael Bernard Barton

absolute proportional benefit (LC or OS) of RT alone over no treatment for radical RT indications. For adjuvant indications, RT benefit was the benefit of RT over surgery alone. For radical indications, the survival benefit was estimated to be equal to the

Full access

Yuefeng Wang, Xinhua Yu, Nan Zhao, Jiajing Wang, Chi Lin, Enrique W. Izaguirre, Michael Farmer, Gary Tian, Bradley Somer, Nilesh Dubal, David L. Schwartz, Matthew T. Ballo, and Noam A. VanderWalde

squamous cell carcinoma of the anus treated with upfront chemotherapy ( supplemental eFigure 1, available with this article at ). Patients who received no treatments, whose treatment was unknown, who received RT alone or surgery, and who were

Full access

Arkadiusz Spychala, Michal Oko, Olga Zając-Spychala, and Witold Kycler

’ knowledge about their disease and treatment, while thyroid-specific HRQOL was measured using Polish version of ThyPRO questionnaire and stress level by COPE Inventory. Assessments were done directly before the surgery (T1), 3 months after (T2), and 6 months

Full access

Mark H. Kawachi

Robot-assisted laparoscopic prostatectomy (RALP) has gained immense popularity. This article examines the most critical outcome measures in prostate cancer surgery and shows the reasons why this technique is gaining in popularity. Operative time, length of stay, blood loss, transfusions, postoperative pain, continence, potency, and cancer control all favor or tend toward improvement and benefit in RALP compared with traditional radical retropubic prostatectomy. In addition, as even greater experience and technological improvements are incorporated, further outcome improvements will be appreciated. RALP is now an accepted treatment option for prostate cancer and may soon be the most desirable treatment of prostate cancer patients.

Full access

Kim Margolin

Advanced germ cell cancer can be cured in most patients using chemotherapy with or without surgery. A small fraction of patients with nonseminomatous tumors (NSGCT) and an even smaller percentage of seminoma patients are destined to have a less favorable outcome, due to an inadequate response to first-line chemotherapy (failure to achieve remission, finding of residual viable carcinoma at post-chemotherapy surgery, or relapse after achieving a remission). Despite the apparent salvage potential for regimens containing ifosfamide or paclitaxel, no proof exists that such combinations are superior to the standard regimen of four cycles of cisplatin, etoposide, and bleomycin (PEB) in the front-line therapy of patients with advanced NSGCT. Other modifications of first-line therapy, such as the addition of paclitaxel or the use of escalated doses of cisplatin, also have failed to increase the cure rate. The use of single or tandem cycles of high-dose chemotherapy (HDT with autologous hematopoietic cell transplant [aHCT]) in various settings (for selected patients with poor prognostic features before therapy, patients predicted to have a poor outcome based on the rate of serum tumor marker decline while on therapy, and patients in relapse or failure to achieve adequate response to standard therapy) has been evaluated in many phase II and a limited number of phase III trials, which are summarized in this review. Important questions that remain to be answered include the role of new agents and the use of more sophisticated techniques to understand prognostic and predictive factors in selecting therapy for GCT.